| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| BioNTech SE | 0 | 2.37% | — | 6 months |
| Emerging Markets Healthcare Partners LLC | 0 | 1.19% | — | 6 months |
| Lake Bleu Innovation Healthcare Master Fund Limited | 0 | 0.85% | — | 6 months |
| Lake Bleu Prime Healthcare Master Fund Limited | 0 | 1.52% | — | 6 months |
| LAV Star Opportunities Limited | 0 | 2.37% | — | 6 months |
| MY Asian Opportunities Master Fund, L.P. | 0 | 2.37% | — | 6 months |
| TruMed | 0 | 4.74% | — | 6 months |
| Worldwide Healthcare Partners LLC | 0 | 0.71% | — | 6 months |
| 富国基金管理有限公司 | 0 | 2.27% | — | 6 months |
| 富国资产管理(香港)有限公司 | 0 | 2.48% | — | 6 months |
| 汇添富基金管理股份有限公司 | 0 | 2.84% | — | 6 months |
| 盘京港景投资基金 | 0 | 2.37% | — | 6 months |
| 苏州苏创生物医药大健康创业投资基金合伙企业(有限合伙) | 0 | 0.95% | — | 6 months |
| 易方达基金管理有限公司 | 0 | 3.49% | — | 6 months |
| 易方达资产管理香港有限公司 | 0 | 0.30% | — | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO's oversubscription ratio of 115.14 signals intense retail demand. The hit rate of 92.34% is exceptionally high for such oversubscription, reflecting a 50% retail clawback under Mechanism A (old) that broadened allocations. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
No tier-level application data is available to assess the efficiency of specific subscription tiers. The high overall hit rate suggests limited tier-based discrimination in allocation, but without granular data, anomalies cannot be identified. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographic data shows 0 total holders with 0% Mainland and 0% Hong Kong participation, indicating missing or unreported statistics. Without reliable demographic figures, no patterns can be drawn. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Dualitybio-B (09606): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

